Labcorp Holdings Inc.

• Labcorp's full test menu will be available through Epic's Aura platform
• Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura
• Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide

BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams, and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide.

Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation

Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows.

"This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."

Benefits for Clinicians and Health Systems

The expanded integration will deliver meaningful benefits including:

• Simplified onboarding and maintenance – Aura's connectivity and content‑management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems.
• Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds.
• Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics.

"Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.

To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic. 

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-and-epic-expand-collaboration-to-advance-diagnostic-integration-across-hospitals-and-health-systems-302768704.html

SOURCE Labcorp

• Results from Operations for first quarter 2026 versus first quarter 2025:
  • Revenue: $3.54 billion vs. $3.35 billion, up 5.8%
  • Diluted EPS: $3.35 vs. $2.52, up 32.8%
  • Adjusted EPS: $4.25 vs. $3.84, up 10.6%
• Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:
  • Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint
  • Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint
• Advanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborations
• Collaborated with Optum.ai to enhance patient and provider experience

BURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2026 and updated full-year guidance.

"Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses," said Adam Schechter, Chairman and CEO of Labcorp. "Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13."

Labcorp continues to advance its strategic priorities:

Be a partner of choice for health systems and regional and local laboratories:

• Announced a nationwide strategic collaboration with Children's Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients.

• Completed the acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs.

Lead in specialty testing:

• Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.

• Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum‑resistant ovarian cancer who may benefit from Merck's KEYTRUDA® and KEYTRUDA QLEX™.

• Launched the Labcorp Fentanyl Visual Urine Test, an FDA‑cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours.

Shape our future through technology and innovation:

• Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer's research.

• Expanded a collaboration with PathAI to deploy AISight® Dx, an FDA-cleared digital pathology platform.

• Announced a collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience.

Drive personalized health solutions:

• Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men's and women's health tests.

• In May, the company will launch MyLabcorp, a secure, AI-powered mobile app that brings an individual's test results and health data together with clinical guidance to help consumers better understand their test results.

Labcorp also remains committed to a disciplined allocation of capital. In the first quarter of 2026, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends. On April 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record at the close of business on May 29, 2026.

Capital Allocation Summary

• At the end of the quarter, Labcorp's cash and cash equivalents balance was $981.1 million and total debt was $6.33 billion. These higher cash and debt balances are due to the pre-funding of maturing debt.

• During the quarter, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends.

Guidance for 2026

Labcorp is updating 2026 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

Use of Adjusted Measures

The company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise "special items" used for certain adjusted financial information are included in the tables accompanying this press release.

The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.

A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the "Events" section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions  on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business  strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company's information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward- looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

- End of Text -

- Tables to Follow -

The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-2026-first-quarter-results-raises-full-year-2026-guidance-302757998.html

SOURCE Labcorp Holdings Inc